(Q38144166)

29 August 2017

title

The potential of sunitinib as a therapy in ovarian cancer (English)

1 reference

Umberto Leone Roberti Maggiore

29 August 2017

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24070205%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Simone Ferrero

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24070205%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

author name string

Mario Valenzano Menada

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24070205%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Pier Luigi Venturini

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24070205%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

language of work or name

English

0 references

publication date

26 September 2013

1 reference

Expert Opinion on Investigational Drugs

29 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24070205%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24070205%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24070205%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

page(s)

1671-1686

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24070205%20AND%20SRC:MED&resulttype=core&format=json

Ovarian cancer: etiology, risk factors, and epidemiology

31 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Monoclonal antibodies therapies for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Major clinical research advances in gynecologic cancer in 2012.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer: a proposal for patient selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Practical considerations in ovarian cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

A phase 3 trial of bevacizumab in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Incorporation of bevacizumab in the primary treatment of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Gemcitabine reverses platinum resistance in platinum-resistant ovarian and peritoneal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Management strategies for recurrent platinum-resistant ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Sunitinib malate for the treatment of solid tumours: a review of current clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Pharmacokinetics of sunitinib in hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

A phase I study of sunitinib plus bevacizumab in advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

A Phase I Study of Sunitinib Plus Capecitabine in Patients With Advanced Solid Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor mo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Potential benefit of Sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Dual-agent molecular targeting of the ErbB2 receptor: killing one bird with two stones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis : a Hoosier Oncology Group trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Sorafenib in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer: A Study of the Princess Margaret Hospital Phase II Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Sorafenib for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Sequential therapy with sorafenib and sunitinib in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

A small molecule-kinase interaction map for clinical kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Sunitinib in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Acute hepatic failure following monotherapy with sunitinib for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Posterior reversible encephalopathy syndrome during sunitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Sunitinib-induced hyperammonemic encephalopathy in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Reversible posterior leucoencephalopathy syndrome in an elderly male on sunitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Biomarkers in the development of anti-angiogenic therapies for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

A Case of Stage III c Ovarian Clear Cell Carcinoma: The Role for Predictive Biomarkers and Targeted Therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Complete remission of recurrent ovarian clear cell carcinoma by chemotherapy with bevacizumab, trabectedin and oxaliplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

Sunitinib malate for the treatment of renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC–IV epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.841138

10.1517/13543784.2013.841138

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24070205%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

1 reference